177Lu-PSMA-617 Clinical Trials

7 actively recruiting trials across 4 locations

Also known as: (177Lu)-PSMA-617, C49H71N9O16, Lutetium Lu 177 vipivotide tetraxetan, Lutetium-177 (177Lu)-PSMA-617, Lutetium-177-PSMA-617 +1 more

Pipeline

Phase 1: 5Phase 2: 2

Top Sponsors

University of California, San Francisco2
Memorial Sloan Kettering Cancer Center2
M.D. Anderson Cancer Center1
Jean-Mathieu Beauregard1
Dana-Farber Cancer Institute1

Indications

Cancer7
Prostate Cancer4
Metastatic Castration-resistant Prostate Cancer3
Metastatic Prostate Cancer2
Liver Disease1

San Francisco, California2 trials

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

University of California, San Francisco

Phase 1

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

University of California, San Francisco

Phase 2

Basking Ridge, New Jersey2 trials

A Study of 177Lu-PSMA-617 in People With Gliomas

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 1

A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 1

Other1 trial

Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)

Phase 1

Boston, Massachusetts1 trial

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

Beth Israel Deaconess Medical Center

Phase 1

Houston, Texas1 trial

177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

MD Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.